Focus: Mereo BioPharma is a UK-based public biotech focused on acquiring and rapidly developing drugs across oncology, endocrinology, women's health, respiratory, and nephrology. The company operates a lean, acquisition-driven model with a diversified pipeline of 50+ programs.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Mereo BioPharma to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Mereo BioPharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Mereo BioPharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Holzer & Holzer, LLC Reminds Investors of April 6, 2026 - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of April 6, 2026 GlobeNewswire
Mereo BioPharma (NASDAQ: MREO) seeks £3.59M allotment authority; S-3 shelf $175M - Stock Titan
Mereo BioPharma (NASDAQ: MREO) seeks £3.59M allotment authority; S-3 shelf $175M Stock Titan
Shareholders Sue Mereo BioPharma (MREO) Over Brittle Bone Drug Claims - TipRanks
Shareholders Sue Mereo BioPharma (MREO) Over Brittle Bone Drug Claims TipRanks
If You Invested $1,000 in Mereo Biopharma (MREO) - Stock Titan
If You Invested $1,000 in Mereo Biopharma (MREO) Stock Titan
CLASS ACTION INVESTOR ALERTS: Bragar Eagel & Squire, P.C. - GlobeNewswire
CLASS ACTION INVESTOR ALERTS: Bragar Eagel & Squire, P.C. GlobeNewswire
Stockholders Who Lost Money Investing in Mereo BioPharma - GlobeNewswire
Stockholders Who Lost Money Investing in Mereo BioPharma GlobeNewswire
Showing 6 of 7 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo